Linker-phosphorylated SMAD2 induces resistance to tyrosine kinase inhibition in EGFR-mutated lung adenocarcinoma

被引：0

作者：

Eunjin, Bae ^{[1
,2
,3
]}

Yoon, Jeonghwan ^{[1
,2
,3
]}

Makino, Yojiro ^{[4
]}

Tamura, Atsumi ^{[4
]}

Lee, Inkyu ^{[2
]}

Han, Jinsoo ^{[3
]}

Ju, Jihyun ^{[5
]}

Sukeda, Aoi ^{[6
]}

Nagao, Toshitaka ^{[6
]}

Ohira, Tatsuo ^{[4
]}

Ikeda, Norihiko ^{[4
]}

Miyazawa, Keiji ^{[7
]}

Kato, Mitsuyasu ^{[8
,9
]}

Kuroda, Masahiko ^{[1
]}

Mamura, Mizuko ^{[1
,2
]}

机构：

[1] Tokyo Med Univ, Dept Mol Pathol, Tokyo, Japan

[2] Kyungpook Natl Univ Hosp, Biomed Res Inst, Daegu, South Korea

[3] Konkuk Univ, Coll Vet Med, Lab Anim Med, Seoul, South Korea

[4] Tokyo Med Univ, Dept Surg, Tokyo, Japan

[5] Catholic Univ, Dept Rheumatol, St Mary Hosp, Seoul, South Korea

[6] Tokyo Med Univ, Dept Anat Pathol, Tokyo, Japan

[7] Univ Yamanashi, Dept Biochem, Kofu, Yamanashi, Japan

[8] Univ Tsukuba, Dept Expt Pathol, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki, Japan

[9] Univ Tsukuba, Fac Med, Tsukuba, Ibaraki, Japan

来源：

CANCER SCIENCE | 2022年 / 113卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P13-1-1

引用

页码：1001 / 1001

页数：1

共 50 条

[1] Linker-Phosphorylated Smad2 and STAT3 Induce Resistance to Tyrosine Kinase Inhibition in Lung Cancer
Makino, Yojiro
Bae, Eunjin
Yoon, Jeong-Hwan
Mamura, Mizuko
Ohira, Tatsuo
Kuroda, Masahiko
Ikeda, Norihiko
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S839 - S839
[2] Cytomorphologic and Molecular Evolution of EGFR-Mutated Lung Adenocarcinomas with Acquired Resistance to Tyrosine Kinase Inhibitors
Doxtader, Erika E.
Brainard, Jennifer A.
Sturgis, Charles D.
Velcheti, Vamsidar
Zhang, Yaxia
LABORATORY INVESTIGATION, 2017, 97 : 93A - 93A
[3] Cytomorphologic and Molecular Evolution of EGFR-Mutated Lung Adenocarcinomas with Acquired Resistance to Tyrosine Kinase Inhibitors
Doxtader, Erika E.
Brainard, Jennifer A.
Sturgis, Charles D.
Velcheti, Vamsidar
Zhang, Yaxia
MODERN PATHOLOGY, 2017, 30 : 93A - 93A
[4] Squamous cell transformation as a mechanism of acquired resistance to tyrosine kinase inhibitor in EGFR-mutated lung adenocarcinoma: a report of two cases
Uruga, Hironori
Fujii, Takeshi
Nakamura, Nobuyuki
Moriguchi, Shuhei
Kishi, Kazuma
Takaya, Hisashi
RESPIROLOGY CASE REPORTS, 2020, 8 (02):
[5] Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma
Sun, Ruizhu
Hou, Zhansheng
Zhang, Yankui
Jiang, Bo
ONCOLOGY LETTERS, 2022, 24 (05)
[6] DOK2 Inhibits EGFR-Mutated Lung Adenocarcinoma
Berger, Alice H.
Chen, Ming
Morotti, Alessandro
Janas, Justyna A.
Niki, Masaru
Bronson, Roderick T.
Taylor, Barry S.
Ladanyi, Marc
Van Aelst, Linda
Politi, Katerina
Varmus, Harold E.
Pandolfi, Pier Paolo
PLOS ONE, 2013, 8 (11):
[7] Human skin biomarkers relationship to response to treatment with tyrosine kinase inhibitors in advanced EGFR-mutated lung adenocarcinoma
Castaneda-Zarraga, Anahi
Rodriguez-Cid, Jeronimo Rafael
Flores-Marinelarena, Rodrigo Rafael
Trinidad-Bibiano, Hector
Martinez-Herrera, Jose Fabian
Sanchez-Rios, Carla Paola
Fernandez-Garibay, Valeria Michelle
Alatorre-Alexander, Jorge Arturo
Martinez-Barrera, Luis
Santillan-Doherty, Patricio Javier
Vega-Memije, Maria Elisa
THORACIC CANCER, 2020, 11 (11) : 3243 - 3251
[8] Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma
Wu, Chiao-En
Chang, Ching-Fu
Huang, Chen-Yang
Yang, Cheng-Ta
Kuo, Chih-Hsi Scott
Hsu, Ping-Chih
Chang, John Wen-Cheng
CANCERS, 2022, 14 (03)
[9] Overcoming resistance to EGF receptor tyrosine kinase inhibitors in EGFR-mutated NSCLC
Saad, Shumaila
Huang, Kan
Halmos, Balazs
LUNG CANCER MANAGEMENT, 2014, 3 (06) : 459 - 476
[10] Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC
Kobayashi, Keigo
Tan, Aaron C.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (04)

← 1 2 3 4 5 →